Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV002034578 | SCV002020878 | pathogenic | not provided | 2019-03-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002034578 | SCV002246679 | pathogenic | not provided | 2023-12-11 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg93*) in the VPS33B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS33B are known to be pathogenic (PMID: 15052268, 16896922). This variant is present in population databases (rs368124813, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with arthrogryposis, renal dysfunction, and cholestasis syndrome (PMID: 16896922). ClinVar contains an entry for this variant (Variation ID: 1323756). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005006046 | SCV005643423 | pathogenic | Arthrogryposis, renal dysfunction, and cholestasis 1; Keratoderma-ichthyosis-deafness syndrome, autosomal recessive; Cholestasis, progressive familial intrahepatic, 12 | 2024-03-05 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003911012 | SCV004723509 | pathogenic | VPS33B-related disorder | 2024-02-15 | no assertion criteria provided | clinical testing | The VPS33B c.277C>T variant is predicted to result in premature protein termination (p.Arg93*). This variant is reported to be causative for ACR (arthrogryposis, renal dysfunction, and cholestasis) syndrome (Gissen et al. 2006. PubMed ID: 16896922). This variant is reported in 0.0046% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in VPS33B are expected to be pathogenic. This variant is interpreted as pathogenic. |